Analysts Set Savara Inc (NASDAQ:SVRA) Price Target at $11.17

Shares of Savara Inc (NASDAQ:SVRA) have been given an average recommendation of “Buy” by the six research firms that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $11.17.

Several research analysts have commented on the stock. Guggenheim upped their price objective on shares of Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Oppenheimer upped their price objective on shares of Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a report on Wednesday, June 26th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Savara in a report on Wednesday, August 14th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $9.00 price target on shares of Savara in a research note on Monday, September 9th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Frazier Life Sciences Management L.P. grew its position in Savara by 103.9% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock valued at $32,874,000 after purchasing an additional 4,157,385 shares during the last quarter. Nantahala Capital Management LLC grew its position in Savara by 198.2% during the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after purchasing an additional 3,443,541 shares during the last quarter. Farallon Capital Management LLC grew its position in Savara by 90.5% during the 2nd quarter. Farallon Capital Management LLC now owns 4,560,000 shares of the company’s stock valued at $18,377,000 after purchasing an additional 2,165,701 shares during the last quarter. Wellington Management Group LLP purchased a new stake in Savara during the 4th quarter valued at about $9,683,000. Finally, First Light Asset Management LLC purchased a new stake in Savara during the 2nd quarter valued at about $8,069,000. 87.93% of the stock is currently owned by institutional investors.

Savara Stock Performance

NASDAQ:SVRA opened at $4.24 on Monday. The company has a fifty day moving average of $4.34 and a 200 day moving average of $4.47. Savara has a 52 week low of $3.12 and a 52 week high of $5.70. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $585.92 million, a P/E ratio of -11.46 and a beta of 0.97.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). On average, research analysts predict that Savara will post -0.44 earnings per share for the current year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.